A detailed history of Lcm Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lcm Capital Management Inc holds 9,190 shares of GILD stock, worth $778,760. This represents 0.39% of its overall portfolio holdings.

Number of Shares
9,190
Previous 8,953 2.65%
Holding current value
$778,760
Previous $655,000 3.82%
% of portfolio
0.39%
Previous 0.43%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$63.15 - $72.88 $14,966 - $17,272
237 Added 2.65%
9,190 $630,000
Q1 2024

May 06, 2024

BUY
$71.58 - $87.29 $1,360 - $1,658
19 Added 0.21%
8,953 $655,000
Q4 2023

Feb 05, 2024

BUY
$73.27 - $83.09 $1,685 - $1,911
23 Added 0.26%
8,934 $723,000
Q3 2023

Nov 07, 2023

BUY
$73.94 - $80.67 $30,463 - $33,236
412 Added 4.85%
8,911 $667,000
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $8,589 - $9,797
113 Added 1.35%
8,499 $655,000
Q1 2023

May 01, 2023

BUY
$77.31 - $88.08 $34,866 - $39,724
451 Added 5.68%
8,386 $695,000
Q4 2022

Jan 24, 2023

BUY
$62.32 - $89.47 $311 - $447
5 Added 0.06%
7,935 $0
Q3 2022

Oct 14, 2022

SELL
$59.54 - $68.01 $1,905 - $2,176
-32 Reduced 0.4%
7,930 $489,000
Q2 2022

Jul 28, 2022

SELL
$57.72 - $65.01 $115 - $130
-2 Reduced 0.03%
7,962 $492,000
Q1 2022

Apr 18, 2022

BUY
$57.92 - $72.58 $19,113 - $23,951
330 Added 4.32%
7,964 $473,000
Q4 2021

Jan 24, 2022

BUY
$64.88 - $73.64 $20,566 - $23,343
317 Added 4.33%
7,634 $554,000
Q3 2021

Oct 15, 2021

BUY
$67.69 - $73.03 $1,218 - $1,314
18 Added 0.25%
7,317 $511,000
Q2 2021

Jul 21, 2021

SELL
$63.47 - $69.35 $8,504 - $9,292
-134 Reduced 1.8%
7,299 $503,000
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $16,320 - $18,621
-272 Reduced 3.53%
7,433 $480,000
Q4 2020

May 12, 2021

BUY
$56.65 - $64.55 $436,488 - $497,357
7,705 New
7,705 $449,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Lcm Capital Management Inc Portfolio

Follow Lcm Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lcm Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Lcm Capital Management Inc with notifications on news.